Dow Jones Top Company Headlines at 5 PM ET: Walt Disney Co. to Lay Off Hundreds | Jamie ...

Dow Jones
03 Jun

Walt Disney Co. to Lay Off Hundreds

Walt Disney is laying off several hundred people globally across multiple divisions, including marketing for film and television, TV publicity, casting and development, and corporate financial operations.

----

Jamie Dimon Says He Isn't Retiring Anytime Soon

The chief executive's would-be successors will need to wait at least a few more years.

----

Tesla sales plunge in France, showing Elon Musk may have a long way to go to restore the brand

Tesla's sales have been under pressure in Europe, even after the rollout of a souped-up Model Y.

----

Campbell's Snack Business Struggles as Consumers Get Pickier About Food Spending

The maker of soups and snacks logged higher sales in its latest quarter and backed its full-year outlook, but it warned about tariffs.

----

Cleveland-Cliffs Stock, Other Steel Shares Soar on Trump's Bombshell Steel Tariff Announcement

President Trump said tariffs on imported steel would go to 50% from 25%. That has investors excited early Monday.

----

Meta Aims to Fully Automate Ad Creation Using AI

Advertising powered by artificial intelligence is a core part of Chief Executive Mark Zuckerberg's vision for the company's future.

----

BioNTech Sets Cancer-Drug Deal With Bristol Myers Squibb

BioNTech and Bristol Myers Squibb have agreed to jointly develop and commercialize BioNTech's BNT327 cancer-drug candidate in a deal potentially worth more than $11 billion to the German drugmaker.

----

Amazon's Pricing Mechanism Could Breach Competition Law, German Regulator Says

Officials said tools that Amazon.com uses to highlight competitively priced goods and filter out overpriced listings in its online marketplace could be breaking competition rules.

----

Why Nvidia Can't Just Quit China

Despite booming demand elsewhere, growth would still be hindered without the world's second-largest economy.

----

Kymera Stock Jumps 41%. New Dermatitis Pill Could Challenge Regeneron Blockbuster.

Its dermatitis drug could win at least 10% of annual sales in dermatitis by 2030-or about $3 billion.

----

Sanofi to Buy Blueprint Medicines for Up to $9.5 Billion in Boost to Pipeline

The pharma giant wants to refreshen its portfolio after some of its internal development programs disappointed in clinical trials.

----

Dior Names Jonathan Anderson Creative Director of Women's, Men's Collections

The fashion house has unified its creative direction under one designer for the first time since founder Christian Dior held the reins.

----

Climate Startups Are Pausing Operations, Cutting Staff and Entering Bankruptcy as Trump Policies Bite

Energy Department announced $3.7 billion worth of funding cuts for clean-energy and climate projects on Friday-in latest blow to green sector.

----

Apple Challenges EU Order to Increase Compatibility with Rivals' Products

The company called the rules deeply flawed, adding the order obliges Apple to share sensitive information with rivals and poses security risks to European customers.

----

Delivery Hero, Glovo Fined $373 Million in EU Probe

Both companies admitted their involvement in the cartel and agreed to settle, the commission said, ultimately leading to a lowered fine.

 

(END) Dow Jones Newswires

June 02, 2025 17:00 ET (21:00 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10